Actinium Pharmaceuticals, Inc. Insider Trading for April 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Actinium Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Actinium Pharmaceuticals, Inc. for April 2016.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 1.97 | 2,500 | 4,925 | 5,453,313 | 5.5 M to 5.5 M (-0.05 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 1.95 | 4,000 | 7,800 | 5,455,813 | 5.5 M to 5.5 M (-0.07 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.06 | 2,408 | 4,960 | 5,459,813 | 5.5 M to 5.5 M (-0.04 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.05 | 3,400 | 6,970 | 5,462,221 | 5.5 M to 5.5 M (-0.06 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.02 | 877 | 1,772 | 5,465,621 | 5.5 M to 5.5 M (-0.02 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.02 | 1,200 | 2,418 | 5,466,498 | 5.5 M to 5.5 M (-0.02 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 400 | 805 | 5,467,698 | 5.5 M to 5.5 M (-0.01 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 7,600 | 15,276 | 5,468,098 | 5.5 M to 5.5 M (-0.14 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 500 | 1,003 | 5,475,698 | 5.5 M to 5.5 M (-0.01 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 200 | 401 | 5,476,198 | 5.5 M to 5.5 M (0.00 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 1,800 | 3,600 | 5,476,398 | 5.5 M to 5.5 M (-0.03 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.09 | 100 | 209 | 5,478,198 | 5.5 M to 5.5 M (0.00 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.08 | 3,692 | 7,679 | 5,478,298 | 5.5 M to 5.5 M (-0.07 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.08 | 1,000 | 2,075 | 5,481,990 | 5.5 M to 5.5 M (-0.02 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.07 | 100 | 207 | 5,482,990 | 5.5 M to 5.5 M (0.00 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.07 | 19,759 | 40,901 | 5,483,090 | 5.5 M to 5.5 M (-0.36 %) |
Apr 26 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.06 | 3,041 | 6,264 | 5,502,849 | 5.5 M to 5.5 M (-0.06 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.05 | 3,700 | 7,585 | 5,505,890 | 5.5 M to 5.5 M (-0.07 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.04 | 9,300 | 18,972 | 5,509,590 | 5.5 M to 5.5 M (-0.17 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.04 | 10,473 | 21,365 | 5,518,890 | 5.5 M to 5.5 M (-0.19 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.03 | 18,224 | 36,995 | 5,529,363 | 5.5 M to 5.5 M (-0.33 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.02 | 4,000 | 8,080 | 5,547,587 | 5.6 M to 5.5 M (-0.07 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 200 | 402 | 5,551,587 | 5.6 M to 5.6 M (0.00 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 600 | 1,200 | 5,551,787 | 5.6 M to 5.6 M (-0.01 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.07 | 3,420 | 7,080 | 5,552,387 | 5.6 M to 5.6 M (-0.06 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.07 | 2,133 | 4,415 | 5,555,807 | 5.6 M to 5.6 M (-0.04 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.07 | 4,517 | 9,328 | 5,557,940 | 5.6 M to 5.6 M (-0.08 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.06 | 8,633 | 17,784 | 5,562,457 | 5.6 M to 5.6 M (-0.15 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.06 | 18,200 | 37,401 | 5,571,090 | 5.6 M to 5.6 M (-0.33 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.05 | 300 | 615 | 5,589,290 | 5.6 M to 5.6 M (-0.01 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.05 | 33,300 | 68,265 | 5,589,590 | 5.6 M to 5.6 M (-0.59 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.04 | 4,800 | 9,792 | 5,622,890 | 5.6 M to 5.6 M (-0.09 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.03 | 2,500 | 5,075 | 5,627,690 | 5.6 M to 5.6 M (-0.04 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.02 | 2,500 | 5,050 | 5,630,190 | 5.6 M to 5.6 M (-0.04 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 11,751 | 23,620 | 5,632,690 | 5.6 M to 5.6 M (-0.21 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.01 | 500 | 1,003 | 5,644,441 | 5.6 M to 5.6 M (-0.01 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 375 | 751 | 5,644,941 | 5.6 M to 5.6 M (-0.01 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 7,562 | 15,125 | 5,645,316 | 5.7 M to 5.6 M (-0.13 %) |
Apr 21 2016 | CTVN | Actinium Pharmaceu ... | Memorial Sloan-Kettering Cance ... | 10% Owner | Sell | S | 2.00 | 49,509 | 99,018 | 5,652,878 | 5.7 M to 5.7 M (-0.87 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | Nicholson, C. David | Director | Option Exercise | A | 1.99 | 75,000 | 149,250 | 75,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | Nicholson, C. David | Director | Buy | P | 2.00 | 5,000 | 10,000 | 15,000 | 10 K to 15 K (+50.00 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | DAVE KAUSHIK J | CEO and Interim CFO | Option Exercise | A | 1.99 | 400,000 | 796,000 | 400,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | DAVE KAUSHIK J | CEO and Interim CFO | Buy | P | 2.01 | 2,000 | 4,020 | 88,500 | 86.5 K to 88.5 K (+2.31 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | DAVE KAUSHIK J | CEO and Interim CFO | Buy | P | 2.02 | 8,000 | 16,160 | 86,500 | 78.5 K to 86.5 K (+10.19 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Option Exercise | A | 1.99 | 500,000 | 995,000 | 500,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Buy | P | 1.99 | 1,500 | 2,985 | 25,000 | 23.5 K to 25 K (+6.38 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Buy | P | 1.98 | 5,000 | 9,900 | 23,500 | 18.5 K to 23.5 K (+27.03 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Buy | P | 2.01 | 1,500 | 3,015 | 18,500 | 17 K to 18.5 K (+8.82 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Buy | P | 2.00 | 2,000 | 4,000 | 17,000 | 15 K to 17 K (+13.33 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | SETH SANDESH | Director | Buy | P | 2.00 | 5,000 | 10,000 | 15,000 | 10 K to 15 K (+50.00 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | CICIC DRAGAN | Chief Medical Offic ... | Option Exercise | A | 1.99 | 50,000 | 99,500 | 50,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | Steinhart Richard I | Director | Option Exercise | A | 1.99 | 75,000 | 149,250 | 75,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | Steinhart Richard I | Director | Buy | P | 2.01 | 2,500 | 5,025 | 2,500 | 0 to 2.5 K |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | TRAVERSA SERGIO | Director | Option Exercise | A | 1.99 | 75,000 | 149,250 | 75,000 | |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | TRAVERSA SERGIO | Director | Buy | P | 2.02 | 1,000 | 2,020 | 3,000 | 2 K to 3 K (+50.00 %) |
Apr 18 2016 | CTVN | Actinium Pharmaceu ... | TRAVERSA SERGIO | Director | Buy | P | 2.02 | 2,000 | 4,040 | 2,000 | 0 to 2 K |